Atripla is a drug owned by Gilead Sciences Llc. It is protected by 33 US drug patents filed from 2013 to 2017. Out of these, 3 drug patents are active and 30 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 28, 2029. Details of Atripla's patents and their expiration are given in the table below.

A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Atripla's patents.

Latest Legal Activities on Atripla's Patents

Given below is the list of recent legal activities going on the following patents of Atripla.

Activity	Date	Patent Number
Critical Events for all Patents
Payment of Maintenance Fee, 8th Year, Large Entity	03 Jul, 2024	US9545414
Payment of Maintenance Fee, 8th Year, Large Entity	12 Oct, 2022	US9018192
Payment of Maintenance Fee, 8th Year, Large Entity	19 May, 2021	US8598185
Payment of Maintenance Fee, 8th Year, Large Entity	12 May, 2021	US8592397
Payment of Maintenance Fee, 4th Year, Large Entity	10 Feb, 2021	US9744181
Payment of Maintenance Fee, 4th Year, Large Entity	02 Jul, 2020	US9545414
Payment of Maintenance Fee, 4th Year, Large Entity	29 Oct, 2018	US9018192
Patent Issue Date Used in PTA Calculation Critical	29 Aug, 2017	US9744181
Recordation of Patent Grant Mailed Critical	29 Aug, 2017	US9744181
Email Notification Critical	10 Aug, 2017	US9744181

While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Atripla and ongoing litigations to help you estimate the early arrival of Atripla generic.

Atripla's Litigations

Atripla been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jul 05, 2001, against patent number US6642245. The petitioner , challenged the validity of this patent, with DIONNE as the respondent. Click below to track the latest information on how companies are challenging Atripla's patents.

Patent	Proceeding Filing Date	Status	Respondent	Petitioner
Live updates
US5935946	June, 2014	Terminated-Denied (17 Dec, 2014)	Gilead Sciences, Inc.	MYLAN PHARMACEUTICALS INC.
US5922695	June, 2014	Terminated-Denied (09 Dec, 2014)	Gilead Sciences, Inc.	Mylan Pharmaceuticals Inc.
US5977089	June, 2014	Terminated-Denied (09 Dec, 2014)	Gilead Sciences, Inc.	Mylan Pharmaceuticals Inc.
US6043230	June, 2014	Terminated-Denied (09 Dec, 2014)	Gilead Sciences, Inc.	Mylan Pharmaceuticals Inc.
US6703396	April, 2002	Decision (04 Apr, 2002)	DIONNE
US6642245	July, 2001	Decision (05 Jul, 2001)	DIONNE

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Download Report

Several oppositions have been filed on Atripla's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Atripla's generic, the next section provides detailed information on ongoing and past EP oppositions related to Atripla patents.

Atripla's Oppositions Filed in EPO

Atripla has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Mar 13, 2009, by Teva Pharmaceutical Industries Ltd.. This opposition was filed on patent number EP04701819A. Click below to reveal the latest opposition data.

Application	Filing Date	Opposition Party	Legal Status
Live updates
EP11167101A	Dec, 2015	Hetero Drugs Ltd.	Revoked
EP11167101A	Dec, 2015	Sandoz AG	Revoked
EP11167101A	Dec, 2015	Accord Healthcare Ltd	Revoked
EP11167101A	Dec, 2015	KELTIE LLP	Revoked
EP11167101A	Dec, 2015	Strawman Limited	Revoked
EP06773194A	Oct, 2009	Teva Pharmaceutical Industries Ltd.	Revoked
EP04701819A	Mar, 2009	Generics [UK] Limited	Revoked
EP04701819A	Mar, 2009	Teva Pharmaceutical Industries LTD.	Revoked

US patents provide insights into the exclusivity only within the United States, but Atripla is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Atripla's family patents as well as insights into ongoing legal events on those patents.

Atripla's Family Patents

Atripla has patent protection in a total of 31 countries. It's US patent count contributes only to 21.3% of its total global patent coverage. 3 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree for Atripla.

Full family tree

Generic Launch

About Atripla

Atripla is a drug owned by Gilead Sciences Llc. It is used for managing HIV-1 infection in adults and pediatric patients aged 12 years and older. Atripla uses Efavirenz; Emtricitabine; Tenofovir Disoproxil Fumarate as an active ingredient. Atripla was launched by Gilead Sciences in 2006.